Israel Englander Clearside Biomedical, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 42,889 shares of CLSD stock, worth $43,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,889

Previous 206,927 79.27%

Holding current value

$43,746

Previous $316,000 82.59%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.08 - $1.58 $177,161 - $259,180	-164,038 Reduced 79.27%	42,889 $55,000
Q1 2024 May 15, 2024	BUY	$1.2 - $2.02 $207,946 - $350,043	173,289 Added 515.16%	206,927 $316,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $1.18 $231 - $401	340 Added 1.02%	33,638 $39,000
Q2 2023 Aug 14, 2023	BUY	$0.97 - $1.48 $32,299 - $49,281	33,298 New	33,298 $37,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $1.5 $105,648 - $158,472	-105,648 Reduced 66.25%	53,814 $60,000
Q3 2022 Nov 14, 2022	SELL	$1.08 - $1.83 $157,958 - $267,652	-146,258 Reduced 47.84%	159,462 $180,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $981,753 - $1.88 Million	-755,195 Reduced 71.18%	305,720 $449,000
Q1 2022 May 16, 2022	BUY	$1.35 - $2.88 $932,062 - $1.99 Million	690,417 Added 186.35%	1,060,915 $2.43 Million
Q4 2021 Feb 14, 2022	BUY	$2.72 - $5.72 $285,670 - $600,748	105,026 Added 39.56%	370,498 $1.02 Million
Q3 2021 Nov 15, 2021	BUY	$4.83 - $7.2 $436,810 - $651,146	90,437 Added 51.67%	265,472 $1.59 Million
Q2 2021 Aug 16, 2021	SELL	$2.32 - $5.38 $26,322 - $61,041	-11,346 Reduced 6.09%	175,035 $852,000
Q1 2021 May 17, 2021	BUY	$2.24 - $4.25 $265,052 - $502,889	118,327 Added 173.87%	186,381 $460,000
Q4 2020 Feb 16, 2021	BUY	$1.32 - $2.74 $89,831 - $186,467	68,054 New	68,054 $186,000
Q3 2020 Nov 16, 2020	SELL	$1.45 - $2.0 $209,710 - $289,256	-144,628 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.55 - $2.41 $113,835 - $176,995	73,442 Added 103.17%	144,628 $272,000
Q1 2020 May 14, 2020	SELL	$1.32 - $3.77 $237,432 - $678,121	-179,873 Reduced 71.65%	71,186 $121,000
Q4 2019 Feb 14, 2020	SELL	$0.62 - $3.4 $18,273 - $100,211	-29,474 Reduced 10.51%	251,059 $728,000
Q3 2019 Nov 14, 2019	SELL	$0.59 - $1.32 $126,426 - $282,853	-214,283 Reduced 43.31%	280,533 $176,000
Q2 2019 Aug 15, 2019	BUY	$0.97 - $1.42 $407,135 - $596,012	419,727 Added 558.97%	494,816 $481,000
Q2 2019 Aug 14, 2019	BUY	$0.97 - $1.42 $72,836 - $106,626	75,089 New	75,089 $213,000
Q1 2019 May 14, 2019	SELL	$1.1 - $1.74 $602,660 - $953,299	-547,873 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.0 - $6.12 $351,555 - $2.15 Million	-351,555 Reduced 39.09%	547,873 $586,000
Q3 2018 Nov 14, 2018	SELL	$6.03 - $11.24 $2.09 Million - $3.9 Million	-346,616 Reduced 27.82%	899,428 $5.53 Million
Q2 2018 Aug 14, 2018	SELL	$8.91 - $14.54 $1.35 Million - $2.21 Million	-151,688 Reduced 10.85%	1,246,044 $13.3 Million
Q1 2018 May 15, 2018	BUY	$5.57 - $14.28 $7.64 Million - $19.6 Million	1,372,303 Added 5396.61%	1,397,732 $15 Million
Q4 2017 Feb 14, 2018	BUY	$5.78 - $9.12 $146,979 - $231,912	25,429	25,429 $178,000

Others Institutions Holding CLSD

# of Institutions

Shares Held

13.4M

Call Options Held

17.6K

Put Options Held

100

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $61.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account